Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

100.40 -1.44 (-1.41%)
Official Closing Price Updated: 7:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
30 31 Next >
Novo Nordisk Is Throwing Down The Gauntlet In Weight Loss As Eli Lilly Ramps Up
Novo Nordisk plans to boost production for its weight-loss shot, Wegovy. 
Via Investor's Business Daily
Novo Nordisk Raises FY22 Earnings Outlook On Robust Ozempic Sales
Via Benzinga
Novo Nordisk: Q3 Earnings Insights
Novo Nordisk (NYSE:NVO) reported its Q3 earnings results on Wednesday, November 2, 2022 at 01:30 AM. Here's what investors need to know about the announcement. Earnings Novo Nordisk beat estimated... 
Via Benzinga
The 7 Best Mutual Funds for Your 401(k)
These mutual funds to add to your 401(k) will help you navigate market downturns such as the one we have experienced this year 
Via InvestorPlace
Prediction: This Could Be This Company's Next Billion-Dollar Product
It would be a major addition to an already rich portfolio. 
Via The Motley Fool
Novo Nordisk Joins NLRP3 Bandwagon, Bets $70M On Ventus' Lead Drug Candidate
Via Benzinga
Novo Nordisk's Subcutaneous Semaglutide Shows Positive Action In Type 2 Diabetes
Via Benzinga
Amgen Shares Leap Higher On Upbeat Outlook For Obesity Treatment
Shares of Amgen soared 5.72% Tuesday and added to those gains Wednesday. The gap-up followed a Morgan Stanley upgrade and increase to the price target. 
Via MarketBeat
Bankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giants
Via Benzinga
Biotech Stocks Well-Positioned For The Fourth Quarter
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
Amgen, The Big Name You Need To Know Going Up Against Novo, Lilly In Obesity
One analyst says a coming-from-behind obesity player could differentiate itself. 
Via Investor's Business Daily
Global Exposure: Value Or Value Trap?
I thought 2022 would be the year that foreign stocks would outperform. However, what started out as a value year for stocks has turned into a lousy year for all stocks (growth and value), with foreign... 
Via Talk Markets
Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes
Via Benzinga
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
Via Benzinga
Ominous Death Cross Forms On Novo Nordisk's Chart
If history is any guide, there may be trouble ahead for shares of Novo Nordisk (NYSE:NVO). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock. 
Via Benzinga
Novo Nordisk's Experimental Diabetes Treatment Achieves Better Blood Sugar Targets Than Insulin Degludec
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels
Via Benzinga
Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout
The deal helps beef up Novo's early-stage efforts in sickle cell disease. 
Via Investor's Business Daily
Forma Therapeutics (FMTX) Stock Soars on Novo Nordisk Acquisition News
There's a major pharmaceutical market deal afoot -- and it's worth over $1 billion -- so FMTX stock is heading higher on the news. 
Via InvestorPlace
After Pfizer, Now Novo Nordisk Beefs Up Its Sickle Cell Portfolio With Forma Therapeutics Deal
Via Benzinga
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst
By Paul Henley, Benzinga 
Via News Direct
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst
In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion. That’s why BioRestorative... 
Via TheNewswire.com
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst
In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion. 
Via Benzinga
3 Stocks to Buy Before the Housing Market Crashes
Economists' expectations of a housing market crash are rising, making these potentially stocks stronger choices in the aftermath. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
By Mark Gilman -- Benzinga 
Via News Direct
Exposures Product Safety
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
Americans with diabetes have been relying on insulin injections to manage their illness for decades. Those injections can be painful, expensive and inconvenient. The daily invasive testing regimen adds... 
Via TheNewswire.com
Exposures Product Safety
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
Americans with diabetes have been relying on insulin injections to manage their illness for decades. Those injections can be painful, expensive and inconvenient. The daily invasive testing regimen adds... 
Via Benzinga
3 Top Stocks to Invest In Right Now
Every investor is looking for the top stocks to invest in. These three options will provide you with both offense and defense. 
Via InvestorPlace
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.